GetTopicDetailResponse(id=33e61e132a8, topicName=TARC, introduction=TARC, content=null, image=null, comments=5, allHits=760, url=https://h5.medsci.cn/topic?id=17132, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=86254, tagList=[TagDto(tagId=86254, tagName=TARC)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1795294, encodeId=81981e95294e5, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, objectTitle=FDA再次拒絕將Intarcia公司的GLP-1受體激動劑皮下滲透泵ITCA 650，用于治療2型糖尿病, objectType=article, longId=189905, objectId=801b18990536, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801b18990536, replyNumber=0, likeNumber=90, createdTime=2020-08-19, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801b18990536, moduleTitle=FDA再次拒絕將Intarcia公司的GLP-1受體激動劑皮下滲透泵ITCA 650，用于治療2型糖尿病, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=801b18990536)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795293, encodeId=6ee71e952934e, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, objectTitle=Blood：血清TARC和IL10水平可指示霍奇金淋巴瘤患者的無進展存活期, objectType=article, longId=159556, objectId=52a61595562b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52a61595562b, replyNumber=0, likeNumber=88, createdTime=2019-04-13, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52a61595562b, moduleTitle=Blood：血清TARC和IL10水平可指示霍奇金淋巴瘤患者的無進展存活期, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=52a61595562b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795292, encodeId=d50d1e952923f, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, objectTitle=Lancet：挑戰(zhàn)指南！血小板功能監(jiān)測并沒有改善冠狀動脈內(nèi)支架植入術(shù)治療ACS老年患者的臨床結(jié)局 (ANTARCTIC), objectType=article, longId=76125, objectId=d59be61251d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d59be61251d, replyNumber=0, likeNumber=93, createdTime=2016-11-20, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d59be61251d, moduleTitle=Lancet：挑戰(zhàn)指南！血小板功能監(jiān)測并沒有改善冠狀動脈內(nèi)支架植入術(shù)治療ACS老年患者的臨床結(jié)局 (ANTARCTIC), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d59be61251d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795291, encodeId=fed41e95291ae, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, objectTitle=The Lancet Oncology：勃林格靶向藥物Giotrif治療肺部鱗狀細胞癌療效優(yōu)于Tarceva, objectType=article, longId=53024, objectId=3eb75302455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb75302455, replyNumber=0, likeNumber=80, createdTime=2015-07-20, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb75302455, moduleTitle=The Lancet Oncology：勃林格靶向藥物Giotrif治療肺部鱗狀細胞癌療效優(yōu)于Tarceva, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3eb75302455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795290, encodeId=9bd81e9529015, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, objectTitle=ntarcia糖尿病藥物臨床三期研究取得顯著成果, objectType=article, longId=40981, objectId=c93f4098194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c93f4098194, replyNumber=0, likeNumber=88, createdTime=2014-10-23, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c93f4098194, moduleTitle=ntarcia糖尿病藥物臨床三期研究取得顯著成果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c93f4098194)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
